Clinical Trial Update: Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

An NCI-sponsored Phase 2 trial evaluated thalidomide in relapsed/refractory chronic lymphocytic leukemia and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED